Olaparib for DNA repair-deficient prostate cancer - one for all, or all for one?

doi:10.1038/s41571-020-0395-x

Comment

. 2020 Aug;17(8):455-456.

doi: 10.1038/s41571-020-0395-x.

Olaparib for DNA repair-deficient prostate cancer - one for all, or all for one?

Emmanuel S Antonarakis¹

Affiliations

PMID: 32447344
DOI: 10.1038/s41571-020-0395-x

Comment

Olaparib for DNA repair-deficient prostate cancer - one for all, or all for one?

Emmanuel S Antonarakis. Nat Rev Clin Oncol. 2020 Aug.

. 2020 Aug;17(8):455-456.

doi: 10.1038/s41571-020-0395-x.

Author

Emmanuel S Antonarakis¹

Affiliation

¹ Departments of Oncology and Urology, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MA, USA. eantona1@jhmi.edu.

PMID: 32447344
DOI: 10.1038/s41571-020-0395-x

No abstract available

PubMed Disclaimer

Comment on

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, Burgents J, Wu W, Kohlmann A, Adelman CA, Hussain M. de Bono J, et al. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28. N Engl J Med. 2020. PMID: 32343890 Clinical Trial.

Cited by

Targeting DNA repair defects in prostate cancer.
Thoma C. Thoma C. Nat Rev Urol. 2020 Aug;17(8):432. doi: 10.1038/s41585-020-0360-6. Nat Rev Urol. 2020. PMID: 32651483 No abstract available.
Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi N, Barata P, Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES. Taza F, et al. JCO Precis Oncol. 2021 Jul 22;5:PO.21.00070. doi: 10.1200/PO.21.00070. eCollection 2021. JCO Precis Oncol. 2021. PMID: 34778690 Free PMC article.
DTX3L-mediated TIRR nuclear export and degradation regulates DNA repair pathway choice and PARP inhibitor sensitivity.
Ye Q, Ma J, Wang Z, Li L, Liu T, Wang B, Zhu L, Lei Y, Xu S, Wang K, Jian Y, Ma B, Fan Y, Liu J, Gao Y, Huang H, Li L. Ye Q, et al. Nat Commun. 2024 Dec 5;15(1):10596. doi: 10.1038/s41467-024-54978-5. Nat Commun. 2024. PMID: 39632881 Free PMC article.
CK2-dependent degradation of CBX3 dictates replication fork stalling and PARP inhibitor sensitivity.
Ma J, Ren D, Wang Z, Li W, Li L, Liu T, Ye Q, Lei Y, Jian Y, Ma B, Fan Y, Liu J, Gao Y, Jin X, Huang H, Li L. Ma J, et al. Sci Adv. 2024 May 24;10(21):eadk8908. doi: 10.1126/sciadv.adk8908. Epub 2024 May 23. Sci Adv. 2024. PMID: 38781342 Free PMC article.

References

1. Antonarakis, E. S. A New molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer. Oncologist 24, 430–432 (2019). - DOI
1. de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1911440 (2020). - DOI - PubMed
1. Dhawan, M. et al. DNA repair deficiency is common in advanced prostate cancer: new therapeutic opportunities. Oncologist 21, 940–945 (2016). - DOI
1. Abida, W. et al. Preliminary results from the TRITON2 study of rucaparib in patients with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann. Oncol. 30 (Suppl. 5), v325–v355 (2019).
1. Abida, W. et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase 2 TRITON2 study. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-0394 (2020). - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

P30 CA006973/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database

[1] Antonarakis, E. S. A New molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer. Oncologist 24, 430–432 (2019). - DOI

[2] Antonarakis, E. S. A New molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer. Oncologist 24, 430–432 (2019). - DOI

[3] de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1911440 (2020). - DOI - PubMed

[4] de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1911440 (2020). - DOI - PubMed

[5] Dhawan, M. et al. DNA repair deficiency is common in advanced prostate cancer: new therapeutic opportunities. Oncologist 21, 940–945 (2016). - DOI

[6] Dhawan, M. et al. DNA repair deficiency is common in advanced prostate cancer: new therapeutic opportunities. Oncologist 21, 940–945 (2016). - DOI

[7] Abida, W. et al. Preliminary results from the TRITON2 study of rucaparib in patients with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann. Oncol. 30 (Suppl. 5), v325–v355 (2019).

[8] Abida, W. et al. Preliminary results from the TRITON2 study of rucaparib in patients with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann. Oncol. 30 (Suppl. 5), v325–v355 (2019).

[9] Abida, W. et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase 2 TRITON2 study. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-0394 (2020). - DOI - PubMed

[10] Abida, W. et al. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase 2 TRITON2 study. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-0394 (2020). - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Olaparib for DNA repair-deficient prostate cancer - one for all, or all for one?

Affiliation

Olaparib for DNA repair-deficient prostate cancer - one for all, or all for one?

Author

Affiliation

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources